CL2013003019A1 - Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. - Google Patents
Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.Info
- Publication number
- CL2013003019A1 CL2013003019A1 CL2013003019A CL2013003019A CL2013003019A1 CL 2013003019 A1 CL2013003019 A1 CL 2013003019A1 CL 2013003019 A CL2013003019 A CL 2013003019A CL 2013003019 A CL2013003019 A CL 2013003019A CL 2013003019 A1 CL2013003019 A1 CL 2013003019A1
- Authority
- CL
- Chile
- Prior art keywords
- benzothiazole
- hiv
- treatment
- pharmaceutical composition
- compounds derived
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477922P | 2011-04-21 | 2011-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003019A1 true CL2013003019A1 (es) | 2014-02-14 |
Family
ID=46028194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003019A CL2013003019A1 (es) | 2011-04-21 | 2013-10-17 | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9006229B2 (es) |
| EP (2) | EP2699558B1 (es) |
| JP (2) | JP5918848B2 (es) |
| KR (1) | KR20140027295A (es) |
| CN (2) | CN103797001B (es) |
| AP (2) | AP2013007249A0 (es) |
| AU (2) | AU2012245187B2 (es) |
| BR (1) | BR112013027096A2 (es) |
| CA (1) | CA2833377C (es) |
| CL (1) | CL2013003019A1 (es) |
| CO (1) | CO6801774A2 (es) |
| CR (1) | CR20130560A (es) |
| EA (1) | EA024952B1 (es) |
| EC (1) | ECSP13013021A (es) |
| ES (2) | ES2707997T3 (es) |
| IL (1) | IL228925A0 (es) |
| MA (1) | MA35804B1 (es) |
| MX (1) | MX2013012266A (es) |
| PE (1) | PE20141066A1 (es) |
| PH (2) | PH12013502180A1 (es) |
| PT (1) | PT2699558T (es) |
| SG (1) | SG194512A1 (es) |
| UA (1) | UA111841C2 (es) |
| WO (1) | WO2012145728A1 (es) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2364314T1 (sl) | 2008-12-09 | 2014-07-31 | Gilead Sciences, Inc. | Modulatorji Tollu podobnih receptorjev |
| PH12013500015A1 (en) | 2010-07-02 | 2013-02-18 | Gilead Sciences Inc | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| PH12013500011A1 (en) | 2010-07-02 | 2013-02-18 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat aids |
| PH12013502180A1 (en) | 2011-04-21 | 2014-01-06 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| US9096586B2 (en) | 2012-04-20 | 2015-08-04 | Gilead Sciences, Inc. | Therapeutic compounds |
| MD4841B1 (ro) | 2012-12-21 | 2023-01-31 | Gilead Sciences, Inc. | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201441197A (zh) * | 2013-01-31 | 2014-11-01 | Shionogi & Co | Ｈｉｖ複製抑制劑 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
| JP6411491B2 (ja) | 2013-07-12 | 2018-10-24 | ギリアード サイエンシス インコーポレーテッド | 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用 |
| NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
| ES2654242T3 (es) | 2014-02-12 | 2018-02-12 | Viiv Healthcare (No.5) Limited | Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| US9975906B2 (en) | 2014-05-16 | 2018-05-22 | Shionogi & Co., Ltd. | Tricyclic heterocycle derivatives having HIV replication inhibitory effect |
| NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| WO2016033009A1 (en) * | 2014-08-27 | 2016-03-03 | Bristol-Myers Squibb Company | Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
| US20160067255A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| SG11201701520TA (en) | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| EP3237414B1 (en) | 2014-12-24 | 2019-05-08 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the tratment of hiv |
| NZ733125A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
| TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| SG10202105371YA (en) | 2014-12-26 | 2021-07-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| BR112017020837A2 (pt) | 2015-04-02 | 2018-07-03 | Gilead Sciences, Inc. | compostos de carbamoilpiridona policíclicos e seu uso farmacêutico |
| RU2720145C2 (ru) | 2015-05-29 | 2020-04-24 | Сионоги Энд Ко., Лтд. | Азотсодержащие трициклические производные, обладающие активностью ингибирования репликации вич |
| WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| AU2016322763A1 (en) | 2015-09-15 | 2018-04-19 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of HIV |
| US10059697B2 (en) | 2015-09-30 | 2018-08-28 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of HIV |
| CR20180321A (es) | 2015-12-15 | 2018-08-21 | Gilead Sciences Inc | Anticuerpos neutralizadores del virus de inmunodeficiencia humana |
| CA3021227C (en) | 2016-08-19 | 2020-11-03 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
| WO2018064080A1 (en) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
| ES2881949T3 (es) | 2016-10-27 | 2021-11-30 | Gilead Sciences Inc | Forma cristalina de base libre de darunavir |
| JP2020503348A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| RU2755710C2 (ru) | 2017-06-30 | 2021-09-20 | Вайв Хелткер Компани | Комбинация, ее применение и способы лечения с использованием указанной комбинации |
| PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| WO2019040102A1 (en) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | THERAPEUTIC HETEROCYCLIC COMPOUNDS |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| US20190151307A1 (en) | 2017-10-24 | 2019-05-23 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| KR20240011880A (ko) | 2017-12-07 | 2024-01-26 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| WO2019144015A1 (en) | 2018-01-19 | 2019-07-25 | Gilead Sciences, Inc. | Metabolites of bictegravir |
| EP3752495B1 (en) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| CA3090280C (en) | 2018-02-16 | 2025-11-25 | Gilead Sciences, Inc. | METHODS AND INTERMEDIARIES FOR PREPARING THERAPEUTIC COMPOUNDS USEFUL IN THE TREATMENT OF A RETROVIRIDAE VIRAL INFECTION |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| IL279189B2 (en) | 2018-07-03 | 2025-12-01 | Gilead Sciences Inc | Antibodies that target hiv gp120 and methods of use |
| EP3817818A1 (en) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| TWI766172B (zh) | 2018-07-30 | 2022-06-01 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| KR102879944B1 (ko) | 2018-09-19 | 2025-11-03 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 예방용 인테그라제 억제제 |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| BR112021008255A2 (pt) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | compostos de 6-azabenzimidazol substituídos como inibidores de hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| AU2020231201B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP4122537A1 (en) | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US20200347036A1 (en) | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CN115996925A (zh) | 2020-06-25 | 2023-04-21 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| CR20230071A (es) | 2020-08-07 | 2023-04-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico |
| AU2021351491C1 (en) | 2020-09-30 | 2025-06-12 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN118355020A (zh) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| KR20250036855A (ko) | 2022-07-12 | 2025-03-14 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| TW202444363A (zh) | 2023-04-19 | 2024-11-16 | 美商基利科學股份有限公司 | 殼體抑制劑之給藥方案 |
| US20250051375A1 (en) | 2023-05-31 | 2025-02-13 | Gilead Sciences, Inc. | Anti-hiv compounds |
| TW202504592A (zh) | 2023-05-31 | 2025-02-01 | 美商基利科學股份有限公司 | 固體形式 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025076542A1 (en) | 2023-10-05 | 2025-04-10 | Jones R Brad | Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025212814A1 (en) | 2024-04-03 | 2025-10-09 | Gilead Sciences, Inc. | Anti-hiv compounds |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895028A (en) * | 1972-09-12 | 1975-07-15 | Tokyo Tanabe Co | Alpha-(2-phenylbenzothiazol-5-yl)propionic acid |
| JPS4994667A (es) * | 1973-01-23 | 1974-09-09 | ||
| FR2453163A1 (fr) * | 1979-04-03 | 1980-10-31 | Rolland Sa A | Derives de benzothiazole, leur procede de preparation et leurs applications en therapeutique |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| GB8403739D0 (en) * | 1984-02-13 | 1984-03-14 | Roussel Lab Ltd | Chemical compounds |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
| ATE167679T1 (de) | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| MX9308016A (es) | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. |
| US5733906A (en) | 1993-10-12 | 1998-03-31 | Eli Lilly And Company | Inhibitors of HIV Protease useful for the treatment of Aids |
| ATE355380T1 (de) | 1993-04-02 | 2006-03-15 | Rigel Pharmaceuticals Inc | Methode zur selektiven inaktivierung der viralen replication |
| JP3287558B2 (ja) | 1993-07-27 | 2002-06-04 | 株式会社半導体エネルギー研究所 | 半導体装置の作製方法 |
| US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
| DE4428932A1 (de) | 1994-08-16 | 1996-02-22 | Hoechst Ag | Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| EP1070040A1 (en) | 1998-04-09 | 2001-01-24 | Merck & Co., Inc. | Oxidation process using periodic acid |
| WO2000063152A1 (en) | 1999-02-22 | 2000-10-26 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Acetylated and related analogues of chicoric acid as hiv integrase inhibitors |
| US20020052323A1 (en) | 2000-08-30 | 2002-05-02 | Jinhai Wang | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents |
| AU2002225731B2 (en) | 2000-11-21 | 2005-04-14 | Sunesis Pharmaceuticals, Inc. | An extended tethering approach for rapid identification of ligands |
| FR2819507B1 (fr) | 2001-01-17 | 2007-09-28 | Inst Rech Developpement Ird | Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus |
| FR2839646B1 (fr) | 2002-05-17 | 2008-04-11 | Bioalliance Pharma | Utilisation de derives de quinoleine a effet anti-integrase et ses applications |
| AU2003262561B2 (en) * | 2002-08-02 | 2008-10-16 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors |
| CN101445493A (zh) * | 2002-08-02 | 2009-06-03 | 泰博特克药品有限公司 | 广谱2-氨基-苯并噻唑磺酰胺类hiv蛋白酶抑制剂 |
| ATE404537T1 (de) | 2002-08-13 | 2008-08-15 | Shionogi & Co | Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung |
| EP2371955A1 (en) | 2002-09-26 | 2011-10-05 | K.U. Leuven Research & Development | Integrase cofactor |
| AU2003302029B8 (en) | 2002-11-20 | 2006-08-17 | Japan Tobacco Inc. | 4-oxoquinoline compound and utilization thereof as HIV integrase inhibitor |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| US20100234409A1 (en) | 2004-05-21 | 2010-09-16 | Lihu Yang | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| US7087610B2 (en) * | 2004-06-03 | 2006-08-08 | Bristol-Myers Squibb Company | Benzothiazole antiviral agents |
| WO2006002185A1 (en) | 2004-06-22 | 2006-01-05 | Smithkline Beecham Corporation | Chemical compounds |
| TWI306401B (en) | 2004-08-13 | 2009-02-21 | Nat Health Research Institutes | Benzothiazolium compounds |
| US20060094755A1 (en) | 2004-10-28 | 2006-05-04 | Bioflexis, Llc | Novel quinoline-based metal chelators as antiviral agents |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| WO2007138472A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| JO2841B1 (en) * | 2006-06-23 | 2014-09-15 | تيبوتيك فارماسيوتيكالز ليمتد | 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV) |
| US8435774B2 (en) | 2006-06-28 | 2013-05-07 | Qiagen Gmbh | Enhancing reactivation of thermostable reversibly inactivated enzymes |
| WO2008053478A2 (en) | 2006-10-30 | 2008-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for inhibiting hiv-1 replication and integrase activity |
| RU2469032C2 (ru) | 2006-12-13 | 2012-12-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы |
| CA2705318C (en) | 2007-11-15 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| BRPI0819328A8 (pt) | 2007-11-15 | 2016-02-10 | Boehringer Ingelheim Int | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos |
| ES2463720T3 (es) | 2007-11-16 | 2014-05-29 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| AU2008323558C1 (en) | 2007-11-16 | 2014-05-01 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0801940D0 (en) | 2008-02-01 | 2008-03-12 | Univ Leuven Kath | Inhibitors of lentiviral replication |
| EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| WO2010059658A1 (en) | 2008-11-20 | 2010-05-27 | Glaxosmithkline Llc | Chemical compounds |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| MX336687B (es) | 2009-06-30 | 2016-01-28 | Siga Technologies Inc | Tratamiento y prevencion de infecciones del virus del dengue. |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| AU2010334958B2 (en) | 2009-12-23 | 2015-02-05 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
| US8846909B2 (en) | 2010-05-24 | 2014-09-30 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| PH12013500015A1 (en) | 2010-07-02 | 2013-02-18 | Gilead Sciences Inc | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| PH12013500011A1 (en) | 2010-07-02 | 2013-02-18 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat aids |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN103429595B (zh) | 2010-11-15 | 2015-10-21 | Viiv保健英国有限公司 | Hiv复制的抑制剂 |
| WO2012065963A2 (en) | 2010-11-15 | 2012-05-24 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| TWI538905B (zh) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| WO2012102985A1 (en) | 2011-01-24 | 2012-08-02 | Glaxosmithkline Llc | Isoquinoline compounds and methods for treating hiv |
| EP2694160A1 (en) | 2011-04-04 | 2014-02-12 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor |
| JP2014511859A (ja) | 2011-04-04 | 2014-05-19 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス |
| EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| ES2742261T3 (es) | 2011-04-15 | 2020-02-13 | Hivih | Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos |
| KR20140025470A (ko) | 2011-04-21 | 2014-03-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 트리아졸로피리딘 |
| MX363696B (es) | 2011-04-21 | 2019-03-28 | Origenis Gmbh | Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas. |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| PH12013502180A1 (en) | 2011-04-21 | 2014-01-06 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| WO2013002357A1 (ja) | 2011-06-30 | 2013-01-03 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| ES2632443T3 (es) | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| WO2013058448A1 (ko) | 2011-10-20 | 2013-04-25 | 한국해양연구원 | 내분비계 장애물질 노출에 대응하는 바다송사리 유전자 및 이를 이용한 수생태계 환경오염 진단 방법 |
| JP6099149B2 (ja) | 2011-10-25 | 2017-03-22 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| US8332160B1 (en) * | 2011-11-17 | 2012-12-11 | Amyris Biotechnologies, Inc. | Systems and methods for engineering nucleic acid constructs using scoring techniques |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| HK1208875A1 (en) | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2013157622A1 (ja) | 2012-04-19 | 2013-10-24 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| US9096586B2 (en) | 2012-04-20 | 2015-08-04 | Gilead Sciences, Inc. | Therapeutic compounds |
| PT2877468T (pt) | 2012-07-12 | 2017-11-21 | Viiv Healthcare Uk Ltd | Compostos e métodos para o tratamento de vih |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20140094609A1 (en) | 2012-10-03 | 2014-04-03 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
| WO2014055618A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
-
2012
- 2012-04-20 PH PH1/2013/502180A patent/PH12013502180A1/en unknown
- 2012-04-20 KR KR1020137030857A patent/KR20140027295A/ko not_active Withdrawn
- 2012-04-20 SG SG2013077110A patent/SG194512A1/en unknown
- 2012-04-20 EP EP12719182.3A patent/EP2699558B1/en active Active
- 2012-04-20 MX MX2013012266A patent/MX2013012266A/es unknown
- 2012-04-20 PE PE2013002347A patent/PE20141066A1/es not_active Application Discontinuation
- 2012-04-20 CA CA2833377A patent/CA2833377C/en active Active
- 2012-04-20 AU AU2012245187A patent/AU2012245187B2/en active Active
- 2012-04-20 EP EP16196723.7A patent/EP3181555B1/en active Active
- 2012-04-20 ES ES16196723T patent/ES2707997T3/es active Active
- 2012-04-20 UA UAA201312204A patent/UA111841C2/uk unknown
- 2012-04-20 CN CN201280029211.7A patent/CN103797001B/zh active Active
- 2012-04-20 EA EA201391395A patent/EA024952B1/ru unknown
- 2012-04-20 AP AP2013007249A patent/AP2013007249A0/xx unknown
- 2012-04-20 CN CN201610177497.3A patent/CN105712948A/zh active Pending
- 2012-04-20 BR BR112013027096A patent/BR112013027096A2/pt not_active IP Right Cessation
- 2012-04-20 PT PT127191823T patent/PT2699558T/pt unknown
- 2012-04-20 US US14/112,473 patent/US9006229B2/en active Active
- 2012-04-20 JP JP2014506609A patent/JP5918848B2/ja active Active
- 2012-04-20 AP AP2015008931A patent/AP2015008931A0/xx unknown
- 2012-04-20 ES ES12719182.3T patent/ES2615734T3/es active Active
- 2012-04-20 WO PCT/US2012/034593 patent/WO2012145728A1/en not_active Ceased
-
2013
- 2013-10-17 CL CL2013003019A patent/CL2013003019A1/es unknown
- 2013-10-17 IL IL228925A patent/IL228925A0/en unknown
- 2013-10-31 CR CR20130560A patent/CR20130560A/es unknown
- 2013-11-14 MA MA36432A patent/MA35804B1/fr unknown
- 2013-11-14 EC ECSP13013021 patent/ECSP13013021A/es unknown
- 2013-11-14 CO CO13268123A patent/CO6801774A2/es unknown
-
2015
- 2015-02-26 US US14/632,771 patent/US9464096B2/en active Active
- 2015-09-11 PH PH12015502056A patent/PH12015502056A1/en unknown
-
2016
- 2016-01-27 JP JP2016012970A patent/JP2016065110A/ja active Pending
- 2016-09-06 US US15/257,482 patent/US9879023B2/en active Active
- 2016-09-29 AU AU2016234985A patent/AU2016234985C1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2014001585A1 (es) | Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih. | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
| CL2016000424A1 (es) | Métodos y composiciones para el arn-guiado tratamiento de la infección por vih | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
| CL2015001702A1 (es) | Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
| CL2014001956A1 (es) | Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2015002860A1 (es) | Antagonistas de la alfa-v-beta-6 integrina | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| PL3381451T3 (pl) | Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. |